Regeneron Pharmaceuticals, Inc. (REGN) said that positive preliminary results from an ongoing proof-of-concept study of evinacumab, REGN1500, in patients with Homozygous Familial Hypercholestrolemia or HoFH were presented at the 84th European Atherosclerosis Society (EAS) Congress in Innsbruck, Austria.
from RTT - Biotech http://ift.tt/1TUUWKc
via IFTTT
No comments:
Post a Comment